STOCKHOLM, June 13, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the interim safety review of the clinical Phase 2a study EXIST showed exidavnemab to be safe and well-tolerated, whereby the second dose cohorts will now be initiated. The EXIST...
Hence then, the article about bioarctic to initiate next cohorts in exidavnemab phase 2a study after positive safety review was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review )
Also on site :
- Five killed in helicopter crash on Africa’s highest mountain (VIDEO)
- transcosmos and V, Inc. launch metaverse creator services for VRChat via Geek Jack, transcosmos's cross-border e-commerce site for entertainment items
- The Christmas Day Storm